Key result
Use of disease modifying therapies in multiple sclerosis patients was associated with higher diastolic blood pressure, plasma glucose, and HDL-C levels compared to DMT-naïve patients.
Why the study?
Do disease modifying therapies modulate cardiovascular risk factors in patients with multiple sclerosis?
Population
298 patients with multiple sclerosis (188 taking disease modifying therapies, 110 DMT-naïve)
Comparison
Disease modifying therapies vs DMT-naïve patients
Design
Cohort
Authors
Loading...
May support CV risk monitoring in MS on DMTs; leaves open causality and needs prospective confirmation.
Observational (n=298)
Do disease modifying therapies modulate cardiovascular risk factors in patients with multiple sclerosis?
In patients with multiple sclerosis, the use of certain disease-modifying therapies like interferon-beta and glatiramer acetate is associated with increased cardiovascular risk factors, highlighting the need for CV risk monitoring in this population.
Sternberg et al. (2013) conducted an observational in Multiple Sclerosis (n=298). Disease modifying therapies (Interferon-beta, Glatiramer acetate, Natalizumab) vs. DMT-naïve patients was evaluated on Cardiovascular risk factors (including blood pressure, lipids, glucose) and MS disease severity. Use of disease modifying therapies in multiple sclerosis patients was associated with higher diastolic blood pressure, plasma glucose, and HDL-C levels compared to DMT-naïve patients.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: